Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

4.170 +0.230 (+5.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Artiva Biotherapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Which stocks are moving on Tuesday?
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Dr. Banerjee’s appointment culminates Artiva’s efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy 
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
These stocks have an unusual volume in today's session
Unusual volume stocks in Tuesday's session 
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Traders are paying attention to the gapping stocks in Tuesday's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Which stocks are moving on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
 
Via Benzinga
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors. 
Via The Motley Fool
Topics Initial Public Offering
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics raised $167 million in its July IPO to advance its innovative cell therapies for autoimmune diseases and cancers. Lead candidate AlloNK, in clinical trials for lupus, is... 
Via Benzinga
Topics Initial Public Offering
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
Ardent Health Slips After Downsized IPO
Shares of Ardent Health slipped in their trading debut on Thursday after the hospital operator reduced its initial public offering from its proposed size and priced below the marketed range. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.